Type 2 diabetes is a highly prevalent disease, especially in elderly and obese patients. Cumulative evidence shows that type 2 diabetes is associated with an increased risk of bone fracture[@b1][@b2]. Several anti-diabetes drugs have been reported to increase the incidence of fractures[@b3][@b4].

Dipeptidyl peptidase-4 (DPP-4) inhibitors, a class of incretin based agents for the treatment of type 2 diabetes, have intermediate efficacy regarding glucose control with a satisfactory tolerability profile[@b5][@b6][@b7]. Data on the effects of DPP-4 inhibitors on fracture risk are conflicting. A meta-analysis of randomized controlled trials (RCTs) suggested that DPP-4 inhibitors reduced the risk of bone fracture[@b8]. However, a recent retrospective population-based cohort study concluded that DPP-4 inhibitors were not associated with fracture risk compared with controls and other non-insulin anti-diabetic drugs (NIADs)[@b9].

The association between DPP-4 inhibitors and the risk of fracture in patients with type 2 diabetes has not been well established. We therefore performed a meta-analysis of randomized trials to provide a more robust answer regarding the risk of fracture in patients with type 2 diabetes treated with DPP-4 inhibitors.

Results
=======

Search results
--------------

A total of 3092 unique titles and abstracts were identified in initial searches of the electronic database. After screening titles and abstracts, we retrieved 343 reports for full text screening. A total of 62 RCTs, including 13 from journals[@b10][@b11][@b12][@b13][@b14][@b15][@b16][@b17][@b18][@b19][@b20][@b21][@b22][@b23] and 49 from the trial registry (available from <https://clinicaltrials.gov>) were included in the final analysis. The details of the study selection flow are described in [Fig. 1](#f1){ref-type="fig"}.

Study characteristics
---------------------

The baseline characteristics of trials are included in [Table 1](#t1){ref-type="table"} and the quality assessment results are listed in [Table S1](#S1){ref-type="supplementary-material"}. A total of 62,206 patients (33,452 in the experimental group and 28,754 in the control group) were included in this analysis, of which 722 had fractures (364 in the experimental group and 358 in the control group). The age of the included patients ranged from 49.7 to 74.9 years. The inhibitors tested in the trials were alogliptin in 7, linagliptin in 13, saxagliptin in 9, sitagliptin in 27, anagliptin in 1, and vildagliptin in 5. The duration of treatment ranged from 12 weeks to 40 months. Forty-three trials were placebo-controlled and 28 used an active comparator, while nine trials included both placebo and active comparator arms. Active comparators included albiglutide, canagliflozin, empagliflozin, glipizide, glimepiride, metformin, voglibose, or thiazolidinediones. Of the 62 trials included in the meta-analysis, 61 were double blind trials.

Risk ratio of fracture
----------------------

A meta-analysis was performed to calculate the overall risk ratio (RR) of fracture associated with DPP-4 inhibitors versus control. Analysis of 62 trials showed that DPP-4 inhibitors were not associated with a significantly increased risk of fracture. The RR of fracture for patients treated with DPP-4 inhibitors compared with that for controls was 0.95 \[95% confidence interval (CI) 0.83--1.10, P = 0.50), with insignificant heterogeneity (I^2^ = 0%) ([Fig. 2](#f2){ref-type="fig"}). The evidence quality was moderate to high ([Table S2](#S1){ref-type="supplementary-material"}).

Subgroup analysis according to drug type
----------------------------------------

Subgroup analysis was performed to determine whether drug type had an effect on the RR of fracture with DPP-4 inhibitors. The RR of fracture with individual DPP-4 inhibitors was 0.79 (95% CI: 0.55--1.13, P = 0.19) for alogliptin (seven trials with 12,085 individuals, enrolling 53 patients with fracture in the experimental group and 61 patients with fracture in the control group), 1.25 (0.66--2.38, P = 0.50) for linagliptin (13 trials with 7638 individuals, enrolling 23 patients with fracture in the experimental group and 10 patients with fracture in the control group), 1.03 (0.87--1.22, P = 0.73) for saxagliptin (nine trials with 21,877 individuals, enrolling 266 patients with fracture in the experimental group and 248 patients with fracture in the control group), 0.66 (0.41--1.06, P = 0.08) for sitagliptin (27 trials with 17,907 individuals, enrolling 17 patients with fracture in the experimental group and 35 patients with fracture in the control group), 4.16 (0.22--78.51, P = 0.34) for anagliptin (one trial with 108 individuals, enrolling three patients with fracture in the experimental group and 0 patients with fracture in the control group) and 0.47 (0.13--1.78, P = 0.27) for vildagliptin (five trials with 2591 individuals, enrolling two patients with fracture in the experimental group and four patients with fracture in the control group). There were no statistically significant differences in the risk of fracture between individual DPP-4 inhibitors (P = 0.22) ([Table 2](#t2){ref-type="table"}). The evidence quality was moderate to high ([Table S2](#S1){ref-type="supplementary-material"}).

Subgroup analysis according to duration
---------------------------------------

Given the potential effect of duration of treatment on the association of DPP-4 inhibitors with risk of fracture, we performed a subgroup analysis stratified according to the length of follow-up. For a duration of ≥52 weeks with 41,641 participants, no statistically significant difference was observed between patients in the DPP4i and control groups (RR = 0.98, 95% CI, 0.84--1.13, P = 0.75), including 662 patients with fracture (332 in the experimental group and 330 in the control group). No significantly increased risk of fracture was observed for a duration of \<52 weeks with 20,565 participants (RR = 0.78, 95% CI, 0.51--1.21, P = 0.28) including 60 patients with fracture (32 in the experimental group and 28 in the control group). There were no statistically significant differences in the risk of fracture according to the length of follow-up (P = 0.35) ([Table 2](#t2){ref-type="table"}). The evidence quality was moderate to high ([Table S2](#S1){ref-type="supplementary-material"}).

Subgroup analysis according to control regimen
----------------------------------------------

Investigation of the effect of inhibitors according to the type of control (active treatment vs. placebo) did not suggest apparent differences (P = 0.76). In trials using active drug for comparison with 16,773 participants, the RR was 0.88 (95% CI: 0.56--1.39, P = 0.58), including 59 patients with fracture (24 in the experimental group and 35 in the control group). In trials using placebo for comparison with 47,953 participants, the RR was 0.95 (95% CI: 0.82--1.10, P = 0.48), including 674 patients with fracture (340 in the experimental group and 334 in the control group) ([Table 2](#t2){ref-type="table"}). The evidence quality was moderate to high ([Table S2](#S1){ref-type="supplementary-material"}).

Risk of specific fractures
--------------------------

Individual specific and non-specific fractures were listed in [Table S3](#S1){ref-type="supplementary-material"}. There was no significant difference between the two groups in the incidence of specific fractures.

Publication bias
----------------

No evidence of publication bias was detected for the RR of fracture in this study ([Figure S1](#S1){ref-type="supplementary-material"}).

Discussion
==========

The effects of DPP-4 inhibitors on bone fractures in type 2 diabetes patients have not been well documented. Here, we performed an updated meta-analysis to provide a summary of current data. Analysis of 62 RCTs demonstrated that the use of DPP-4 inhibitors does not affect the risk of bone fracture compared with placebo or other antidiabetic medications in patients with type 2 diabetes. The results were consistent across subgroups defined by type of DPP-4 inhibitor, type of control, and length of follow-up.

Our results were in line with a recently published retrospective population-based cohort study that examined 216,816 patients and suggested that DPP-4 inhibitors were not associated with fracture risk compared with controls or other NIADs[@b9]. Our study was inconsistent with that of Monami *et al*.[@b8], which showed a 40% reduction of fracture risk in DPP4-I users compared with patients taking other anti-diabetic drugs or placebo[@b24][@b25][@b26]. However, the positive effect observed in this study could be related to the limited number of trials included in the analysis. Compared with the study by Monami *et al*.[@b8], our study has several strengths. First, we collected data from 62 randomized trials (N = 62,206), which together involved approximately three times as many patients as those included in the study by Monami et al. (N = 21,055)[@b8]. Second, we explored sources of heterogeneity with three priori subgroup hypotheses and the results remained robust.

Out results were largely influenced by a large RCT (N = 16,492) that compared saxagliptin with placebo and showed that the incidence of bone fracture was comparable between saxagliptin and placebo users[@b16]. However, the results remained robust after omitting that trial.

Glucagon-like peptide-1 (GLP-1) has been suggested to have a beneficial effect on bone[@b27][@b28]. The enzyme DPP-4 is involved in the degradation of GLP-1, and DPP-4 inhibitors are able to inhibit this process[@b9]. However, a recent meta-analysis highlighted that the use of GLP-1 receptor agonists does not modify the risk of bone fracture in patients with type 2 diabetes compared with the use of other antidiabetic medications[@b29]. Moreover, a recent *in vivo* study showed that MK-0626, a DPP-4 inhibitor, had neutral effects on cortical and trabecular bone in an animal model of type 2 diabetes, and MK-0626 did not alter osteoblast differentiation[@b30]. Thus, bone quality may be more important than bone density in predicting the increased risk for fractures in patients with type 2 diabetes[@b31].

The present meta-analysis had several limitations. First, the duration of the trials included was not long enough to analyze the effects of DPP-4 inhibitors on the risk of bone fracture. We performed a subgroup analysis according to duration (≥52 weeks vs. \<52 weeks) and found that the risk of fracture in different length of follow up were not significantly different. Second, fractures were not the primary endpoints in any of the included trials and were reported only as serious adverse events. Finally, no data could be obtained about gender and menopausal status. Therefore, trials with a longer follow-up duration and bone fracture as the primary endpoint are needed to further investigate the effects of DPP-4 inhibitors on fracture risk.

In summary, the current analysis suggested that the use of DPP-4 inhibitor does not decrease the risk of fracture in patients with type 2 diabetes. Given the negative effects of certain anti-diabetic drugs on bone, the results of the present study may be disappointing; however, a neutral effect on bone is still reassuring.

Methods
=======

Data Sources and Searches
-------------------------

An extensive search of Medline, Embase, and Cochrane Central Register of Controlled Trials was performed by two of the investigators (J.F. and J.Z.). Data were collected on all randomized clinical trials in humans up to March 2016. Discrepancies in abstracted data between the reviewers were resolved by a third reviewer (Z.Z.). The search terms used were as follows: "DPP-4", "dipeptidyl peptidase 4", "alogliptin", "linagliptin", "saxagliptin", "sitagliptin", "vildagliptin", "anagliptin", and "dutogliptin". The results of unpublished data were identified through a search of the [www.clinicaltrials.gov](http://www.clinicaltrials.gov) website.

Study Selection
---------------

The trials that met the following criteria were included in the analysis: (a) randomized clinical trials in type 2 diabetes patients; (b) duration of at least 12 weeks; (c) patients assigned to treatment with DPP-4 inhibitors compared with placebo or active drugs; (d) data on bone fracture was available; and (f) trials with two zero events were excluded from the analysis.

Data Extraction and Quality Assessment
--------------------------------------

The following information was extracted independently from eligible RCTs by two of the investigators (Y.H. and C.G.): author's name, year of publication, study design, sample size, number of treatment groups, length of follow-up, mean age, and registry number. In addition, for trials in which fracture data had not been published previously, the investigators abstracted the relevant numbers from their previously established databases of adverse events. The quality of included trials was assessed using the Jadad score[@b32], which was only used for descriptive purposes. Any discrepancies in abstracted data between the reviewers were resolved by a third reviewer (Z.Z.).

Data analysis
-------------

The meta-analysis was performed following the PRISMA checklist[@b33]. The main outcome was bone fracture reported as a serious adverse event. Trials were pooled using the Mantel-Haenszel method to calculate RRs and their 95% CIs. P \< 0.05 was considered significant. For studies reporting zero fracture events in a treatment or control arm, a classic half-integer continuity correction was used to calculate the RR and variance. Heterogeneity between studies was assessed by using the χ2 test and the I^2^ statistic. Selection of the fixed- or random-effects model depended on the result of the Cochrane's *Q* test. An I^2^ value of 50% was considered to indicate significant heterogeneity between trials[@b34]. A fixed effects model was applied if there was no statistical heterogeneity among the studies; otherwise, the random effects model was used[@b34]. Pre-defined subgroup analyses were performed for trials that included different types of DPP-4 inhibitors (alogliptin, linagliptin, saxagliptin, sitagliptin, anagliptin, and vildagliptin), different types of control (active treatment vs. placebo), and different lengths of follow-up (≥52 weeks vs. \<52 weeks). Finally, publication bias was evaluated through funnel plots. Meta-analyses were performed using Review Manager 5.1 software. The criteria of the Grading of Recommendations Assessment, Development and Evaluation were used to evaluate the quality of evidence by outcome.[@b35]
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###### Characteristics of studies included in primary analysis.

  Study                     NCT code           DPP-4       Comparator(s)       N. of patients   Duration (weeks)   Age (years)   HbA1c (%)   Fracture        
  ----------------- ------------------------- ------- ----------------------- ---------------- ------------------ ------------- ----------- ---------- ----- -----
  Bosi[@b10]               NCT00432276         ALOG        Pioglitazone             404               399              52           55         8.3       6     4
  NCT00286468              NCT00286468         ALOG           Placebo               401                99              26           57          8        1     0
  NCT01023581              NCT01023581         ALOG      Placebo/metformin          450               334              26          53.5        8.5       0     1
  NCT00856284              NCT00856284         ALOG          Glipizide              1765              874              104         55.4        7.6       6     4
  NCT00328627              NCT00328627         ALOG    Placebo/pioglitazone         1037              517              26          54.4        8.6       0     1
  NCT00707993              NCT00707993         ALOG          Glipizide              222               219              52          69.9         NR       2     1
  White[@b11]              NCT00968708         ALOG           Placebo               2701              2679          40 months      60.9         8       38    50
  NCT01183013              NCT01183013         LINA           Placebo               392               409              54          57.1        8.11      1     0
  NCT00915772              NCT00915772         LINA      Placebo/metformin          171               170              54          55.8        7.5       1     1
  NCT00798161              NCT00798161         LINA      Placebo/metformin          428               363              24          55.2        8.91      1     1
  NCT01438814              NCT01438814         LINA           Placebo               344               345              14           53          NR       0     1
  NCT00601250              NCT00601250         LINA           Placebo               523               177              24          56.5        8.08      2     0
  NCT01084005              NCT01084005         LINA           Placebo               162                79              24          74.9        7.78      2     0
  NCT00954447              NCT00954447         LINA           Placebo               631               630              52           60         8.3       6     5
  NCT00602472              NCT00602472         LINA           Placebo               792               263              24          58.1        8.14      3     0
  NCT00800683              NCT00800683         LINA           Placebo                68                65              52          64.4        8.2       2     0
  NCT00621140              NCT00621140         LINA           Placebo               336               167              24          55.7         8        1     2
  NCT01204294              NCT01204294         LINA          Metformin              228               124              52          60.9         NR       1     0
  NCT01215097              NCT01215097         LINA           Placebo               205               100              24          55.5        7.99      1     0
  Barnett[@b12]            NCT01084005         LINA           Placebo               162                79              24          74.9        7.78      2     0
  Barnett[@b13]            NCT00757588         SAXA           Placebo               304               151              52          57.2        8.7       2     3
  Hollander[@b14]          NCT00295633         SAXA           Placebo               381               184              24           54          8        5     1
  Scirica[@b15]            NCT01107886         SAXA           Placebo               8280              8212          2.9 years       65          NR      241   240
  NCT01006603              NCT01006603         SAXA         Glimepiride             359               359              52          72.6         NR       4     1
  NCT00121667              NCT00121667         SAXA           Placebo               564               179              206         54.57       8.1       4     0
  NCT00575588              NCT00575588         SAXA          Glipizide              428               430              52          57.55       7.7       4     2
  NCT00614939              NCT00614939         SAXA           Placebo                85                85              52          66.5         NR       0     1
  NCT00327015              NCT00327015         SAXA      Placebo/metformin          643               328              76           52         9.5       3     0
  NCT00661362              NCT00661362         SAXA           Placebo               283               287              24           54         7.9       3     0
  NCT00509236              NCT00509236         SITA          Glipizide               64                65              54          59.5         NR       2     0
  NCT01076088              NCT01076088         SITA      Placebo/metformin          367               377              24          52.7        8.7       0     3
  NCT00509262              NCT00509262         SITA          Glipizide              211               212              54          64.2        7.8       1     1
  NCT01076075              NCT01076075         SITA        Pioglitazone             210               212              54          54.9        8.4       0     1
  NCT00885352              NCT00885352         SITA           Placebo               157               156              26          56.1        8.7       0     1
  NCT00395343              NCT00395343         SITA           Placebo               322               319              24          57.8        8.7       1     0
  NCT00722371              NCT00722371         SITA    Placebo/pioglitazone         691               693              54           57          NR       3     1
  NCT01462266              NCT01462266         SITA           Placebo               329               329              24          58.8         NR       0     1
  NCT00305604              NCT00305604         SITA           Placebo               102               104              24          71.9        7.8       0     2
  NCT00411554              NCT00411554         SITA          Voglibose              163               156              12          60.7        7.8       0     1
  NCT00103857              NCT00103857         SITA     Placebo/ metformin          372               540              104         53.4         9        1     3
  NCT01177813              NCT01177813         SITA        Empagliflozin            223               448              31           55          NR       0     1
  NCT00449930              NCT00449930         SITA          Metformin              528               522              24           56         7.3       1     0
  NCT00701090              NCT00701090         SITA         Glimepiride             516               519              30          56.3        7.5       2     1
  NCT00086515              NCT00086515         SITA          Glipizide              464               237              24          54.5         8        0     1
  NCT01098539              NCT01098539         SITA         Albiglutide             246               249              26          63.3         NR       0     2
  NCT00086502              NCT00086502         SITA           Placebo               175               178              24          56.2         8        0     1
  NCT00094770              NCT00094770         SITA          Glipizide              588               584              104         56.7        7.7       3     3
  NCT01289990              NCT01289990         SITA    Placebo/empagliflozin        223               223              76          55.6         NR       0     2
  NCT00482729              NCT00482729         SITA           Placebo               625               621              44          49.7        9.87      1     2
  NCT00397631              NCT00397631         SITA           Placebo               261               259              24          50.9        9.5       1     0
  NCT01106677              NCT01106677         SITA        Canagliflozin            366               735              52          55.4         NR       0     1
  NCT01137812              NCT01137812         SITA        Canagliflozin            378               377              52          56.5         NR       1     2
  NCT01106690              NCT01106690         SITA        Canagliflozin            115               227              52          57.4         NR       0     2
  NCT00881530              NCT00881530         SITA           Placebo                56                56              78          58.6         NR       0     1
  Iwamoto[@b16]                NR              SITA          Voglibose              163               156              12          60.7        7.8       0     1
  Raz[@b17]                NCT00337610         SITA           Placebo                96                94              30          54.8        9.2       0     1
  Bosi[@b18]         NCT00468039 NCT00382096   VILDA          Placebo               292               292              24          52.8        8.65      1     0
  Fonseca[@b19]            NCT00099931         VILDA          Placebo               144               152              24          59.2        8.4       0     1
  Iwamoto[@b20]                NR              VILDA         Voglibose              188               192              12          60.3        7.5       0     2
  Pan[@b21]                    NR              VILDA          Placebo               294               144              24          54.2        8.05      1     0
  Scherbaum[@b22]          NCT00101712         VILDA          Placebo               156               155              52          63.3        6.7       0     1
  Yang[@b23]                   NR              ANAG           Placebo                60                48              24          56.2        7.14      3     0

ALOG, alogliptin; LINA, linagliptin; SAXA, saxagliptin; SITA, sitagliptin; VILDA, vildagliptin; ANAG, anagliptin;NR, nor reported.

###### Risk ratio of fracture by subgroup analyses.

  Subgroup                    Studies n   No. of fracture   No. of participants   Risk ratio (95% CI)   P Value                              
  -------------------------- ----------- ----------------- --------------------- --------------------- --------- -------------------- ------ ------
  Overall Individual DPP-4       62             364                 358                  33452           28754    0.95 (0.82, 1.10)    0.50    NA
  Alogliptin                      7             53                  61                   6972            5113     0.79 (0.55, 1.14)    0.20   0.37
  Linagliptin                    13             23                  10                   4667            2971     1.19 (0.60, 2.38)    0.62     
  Saxagliptin                     9             266                 248                  11662           10215    1.02 (0.86, 1.21)    0.84     
  Sitagliptin                    27             17                  35                   8422            9485     0.67 (0.39, 1.15)    0.15     
  Anagliptin                      1              3                   0                    68              40      4.16 (0.22, 78.51)   0.34     
  Vildagliptin                    5              2                   4                   1661             930     0.50 (0.12, 2.05)    0.33     
  Duration                                                                                                                                   
   ≥52 weeks                     28             332                 330                  21645           19996    0.97 (0.83, 1.13)    0.69   0.37
   \<52 weeks                    34             32                  28                   11807           8758     0.76 (0.46, 1.27)    0.29     
  Comparators                                                                                                                                
   Active drug                   28             24                  35                   7594            9179     0.91 (0.54, 1.52)    0.71   0.88
   Placebo                       43             340                 334                  26235           21718    0.95 (0.81, 1.10)    0.44     

NA, not applicable.

[^1]: These authors contributed equally to this work.
